Catherine Traullé

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Philippe Moreau, Hervé Avet‐Loiseau, Thierry Façon et al. · Blood · 2011 · 302 citations

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

Hervé Avet‐Loiseau, Michel Attal, L. Campion et al. · Journal of Clinical Oncology · 2012 · 223 citations · Full text

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Xavier Leleu, Michel Attal, Bertrand Arnulf et al. · Blood · 2013 · 208 citations

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

Laurence Lodé, Marion Eveillard, Valérie Trichet et al. · Haematologica · 2010 · 145 citations · Full text

Hematological Malignancy, Tumor Biology, Chromatin +15

Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome

Catherine Thiéblemont, A. Grossoeuvre, Roch Houot et al. · Annals of Oncology · 2007 · 129 citations

Lymphoid Neoplasia, Geriatric Oncology, Elderly Patients +7